Figure 6 . Anti-CXCL16 antibody ameliorated cecal ligation and puncture (CLP)-induced severe sepsis. C57BL/6 mice were subjected to severe CLP; and then 10 μg of anti-mouse CXCL16 monoclonal antibody was injected intraperitoneally at 2 hour after severe CLP. IgG2A control antibody was delivered in a similar way. (A) Survival of septic mice (n = 12 per group) following administration with anti–CXCL16 antibody or control antibody after severe CLP. Comparison between groups was performed by Kaplan-Meier analysis followed by log-rank tests. Results are representative of three independent experiments.p <0.05 when compared with septic mice treated with IgG control. (B) Representative examples of hematoxylin and eosin–stained lung, liver, and kidney tissues from septic mice (n = 6) treated with or without anti-CXCL16 neutralizing antibodies after severe CLP. (C) Histological scores for lung, liver, and kidney in septic mice (n = 6) treated with or without anti-CXCL16 neutralizing antibodies after severe CLP. p <0.05, p <0.01 when compared with septic mice treated with isotypical IgG control (Mann-Whitney U test). (D) ALT, AST, LDH, and creatinine levels in septic mice (n = 6) treated with or without anti- CXCL16 neutralizing antibodies after severe CLP.p <0.05, p <0.01 when compared with septic mice treated with isotypical IgG control (Mann-Whitney Utest).